

AMSER Case of the Month

August 2020

“Umbilical Hernia”

Jothika Challapalli, MS4

Drexel University College of Medicine

Matthew Hartman, MD

Allegheny Health Network



Patient Presentation

- **HPI:** 33 yo male presenting with progressively enlarging umbilical region mass felt to represent an umbilical hernia, first noticed 8 months prior to visit
- **ROS:** Denies abdominal pain, N/V, fevers, chills, SOB, jaundice, change in bowel habits or appetite, urinary symptoms, weight loss
- **PMH/Meds:** None, no medications
- **PSH:** None
- **SH:** Never smoker, social alcohol use
- **PE:** Reducible umbilical hernia, otherwise within normal limits
- **LABS:** No pertinent labs

What Imaging Should We Order? ACR Appropriateness Criteria

Variant 2:

Palpable abdominal mass. Suspected abdominal wall mass. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US abdomen	Usually Appropriate	○
CT abdomen with IV contrast	Usually Appropriate	☼☼☼
MRI abdomen without and with IV contrast	Usually Appropriate	○
MRI abdomen without IV contrast	May Be Appropriate	○
CT abdomen without IV contrast	May Be Appropriate	☼☼☼
CT abdomen without and with IV contrast	Usually Not Appropriate	☼☼☼☼
FDG-PET/CT skull base to mid-thigh	Usually Not Appropriate	☼☼☼☼
Radiography abdomen	Usually Not Appropriate	☼☼
Fluoroscopy contrast enema	Usually Not Appropriate	☼☼☼
Fluoroscopy upper GI series	Usually Not Appropriate	☼☼☼
Fluoroscopy upper GI series with small bowel follow-through	Usually Not Appropriate	☼☼☼

This imaging modality was ordered by the surgeon



Findings (unlabeled)





Findings (labeled)

Mixed solid and cystic mass with pathognomonic (punctate, stippled, curvilinear and peripheral calcifications

Malignant appearing ascites

Mass extends from umbilicus to dome of bladder



Final Dx:

Metastatic Urachal Adenocarcinoma

Case Discussion

- Follow-up laboratory workup revealed CEA (carcinoembryonic antigen) elevated at 32.6 ng/mL
- Diagnostic laparoscopy confirmed well-differentiated urachal adenocarcinoma, mucinous type
- Surgical resection 10 days later revealed extension beyond bladder into peritoneum and focally involving liver capsule (stage pT4)

Urachal Neoplasms

- Very rare, <1% of all bladder cancer → limited literature
- Initial presenting symptom usually hematuria, others include mucinuria, recurrent UTIs, local pain, or umbilical discharge
- Urachus: tissue of origin
 - Residua of the embryological allantois and extends from the bladder dome to the umbilicus within the extraperitoneal, retropubic space (cave of Retzius)
 - Usually seals off into a fibrous cord (median umbilical ligament)
 - Can persist with 4 possible remnant types: patent urachus (unsealed along entire extent), umbilical-urachal sinus (unsealed at umbilicus), vesicourachal diverticulum (unsealed at bladder), urachal cyst (unsealed along its midportion)
- Remnants at risk for recurrent infections and neoplasm formation – most common malignancy is adenocarcinoma, mainly mucinous type (type associated with calcifications)

Staging

- No AJCC TNM staging system accepted
- Sheldon Staging System best known/most used
 - pT1 – no invasion beyond the urachal mucosa
 - pT2 – invasion confined to the urachus
 - pT3 – local extension to the (a) bladder, (b) abdominal wall, (c) viscera other than the bladder
 - pT4 – metastasis to (a) regional lymph nodes, (b) distant sites

Management

- Silent early lesions with propensity for local growth and tendency to metastasize – usually present at stage pT3 or higher
- High likelihood of recurrence documented in the literature
- Primary therapeutic approach = surgical resection with partial or radical cystectomy and *en bloc* resection of the urachal ligament with the umbilicus (+/- chemotherapy)

References:

- Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. *Am J Surg Pathol*. 2009;33(5):659-668. doi:10.1097/PAS.0b013e31819aa4ae
- Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. *J Urol*. 1984;131(1):1-8. doi:10.1016/s0022-5347(17)50167-6
- Paner GP, Lopez-Beltran A, Sirohi D, Amin MB. Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. *Adv Anat Pathol*. 2016;23(2):71-83. doi:10.1097/PAP.0000000000000110
- Urachal Adenocarcinoma. American Urological Association. <https://www.auanet.org/education/auauniversity/education-products-and-resources/pathology-for-urologists/urinary-bladder/non-urothelial-carcinomas/urachal-adenocarcinoma>.
- Koster IM, Cleyndert P, Giard RWM. Urachal Carcinoma. *Radiographics*. 2009; 29(3): 939-942. doi.org/10.1148/rg.293085152.